ARTELO BIOSCIENCES INC (ARTL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.27-5.42%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ARTL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ARTL — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-08-27
Material Modification to Rights of Security Holders. The information set forth in
Why it matters: New trial results can show whether ART27.13 may help people with cancer-related appetite and weight loss.
Watch forA company update reports new CAReS results that show a benefit on a stated trial measure.
Also watch forA company update reports no gain on a stated measure, a safety concern, or a trial delay.
Why it matters: A signed deal could bring support for ART27.13. The company cited interim Phase 2 data in its partnership talks.
Supportive ifA company filing or release names a partner and states the deal covers ART27.13.
Worry ifThe next company update says talks ended, or gives no partner news and reports no new ART27.13 progress.
Why it matters: Artelo has ongoing losses and negative cash flow. New funding can help pay for trials, while more cash use can raise funding needs.
Watch forThe November 11 report shows more cash from operations than the last reported quarter. Or it names new funding.
Also watch forThe November 11 report shows cash from operations at or below the prior low of -$3.5 million. It reports no new funding.
Why it matters: The reverse split changed the share count and adjusted warrants. Later filings can show whether new shares or warrants add to dilution.
Worry ifA later filing shows new shares issued or warrants exercised. This raised the share count above about 547,774.
Less concerning ifA later filing shows no new share issue or warrant exercise, and the share count stays near 547,774.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$332 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $1,395 loss on $10,000 · 14.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,771 loss on $10,000 · 97.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: ART26.12 is in clinical development for nerve pain. A dated trial step would show pipeline progress.
Supportive ifA company filing or release names a new ART26.12 trial start, enrollment target, or results date.
Worry ifA company update reports an ART26.12 delay, trial stop, or no new milestone in its next pipeline update.